Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Oslo Bors  >  BerGenBio ASA    BGBIO   NO0010650013

BERGENBIO ASA

(BGBIO)
  Report
Delayed Quote. Delayed Oslo Bors - 05/29 10:25:23 am
39.35 NOK   -2.24%
05/29BERGENBIO ASA : Notice of Extraordinary general meeting
AQ
05/29BERGENBIO ASA : Notice of Extraordinary general meeting
AQ
05/20BERGENBIO : Results for the first quarter 2020
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

BerGenBio ASA: Notice of Extraordinary general meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
05/29/2020 | 06:03am EDT

Bergen, Norway, 29 May 2020 - Notice is hereby given of an Extraordinary General Meeting in BerGenBioASA will be held on 19 June 2020 at 15:00 hours (CET) at the Company's offices in Møllendalsbakken 9, 5009 Bergen.

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and is available

at https://www.bergenbio.com/investors/general- meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

Due to COVID-19 related restrictions and the advice from the Norwegian government all shareholders are encouraged to exercise their shareholder rights without physical attendance at the general meeting, either through advance electronically voting through VPS Investor Services or by using the enclosed proxy form to provide proxy to the Chairman Sveinung Hole (or the person he appoints).

Notice of attendance, advance vote or proxy for the Extraordinary General Meeting can be registered through the company's website or VPS Investor Service. All registered shareholders will receive a reference number and a pin code required for registration through the company's website. Reference number and pin code will be received either by VPS Investor Service or by post depending if the shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS to save environment impact.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers and infectious diseases. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapyin lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel,BerGenBio is developing companion diagnostic tests to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

http://publish.ne.cision.com//Release/ViewReleaseHtml/3C84E27A48AF00CCE0C856B0705FC7D6

https://mb.cision.com/Main/15728/3123080/1255896.pdf

https://mb.cision.com/Public/15728/3123080/acc5076dab2f0907.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BERGENBIO ASA
05/29BERGENBIO ASA : Notice of Extraordinary general meeting
AQ
05/29BERGENBIO ASA : Notice of Extraordinary general meeting
AQ
05/20BERGENBIO : Results for the first quarter 2020
AQ
05/19BERGENBIO ASA : Results for the first quarter 2020
AQ
05/13BERGENBIO ASA : Invitation to first quarter 2020 results webcast presentation
AQ
05/06BERGENBIO : RAISES NOK500m VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT
AQ
05/05BERGENBIO : Private placement successfully placed
PU
05/05BERGENBIO : RAISES NOK500m (?45.4m) VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT
AQ
05/05BERGENBIO : RAISES NOK500m (€45.4m) VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT
AQ
05/05BERGENBIO : Key information related to the subsequent offering
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -218 M -22,5 M -22,5 M
Net cash 2020 228 M 23,4 M 23,4 M
P/E ratio 2020 -14,9x
Yield 2020 -
Capitalization 3 413 M 351 M 351 M
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees 28
Free-Float 83,9%
Chart BERGENBIO ASA
Duration : Period :
BerGenBio ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BERGENBIO ASA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 57,16 NOK
Last Close Price 39,35 NOK
Spread / Highest target 67,7%
Spread / Average Target 45,2%
Spread / Lowest Target 22,8%
EPS Revisions
Managers
NameTitle
Richard Stuart Godfrey Chief Executive Officer
Sveinung Hole Chairman
Rune Skeie Chief Financial Officer
James Bradley Lorens Chief Scientific Officer
Alison Messom Director-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
BERGENBIO ASA61.60%351
GILEAD SCIENCES19.78%97 628
VERTEX PHARMACEUTICALS31.52%74 661
REGENERON PHARMACEUTICALS63.21%68 243
WUXI APPTEC CO., LTD.15.61%33 459
GENMAB A/S39.05%20 072